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in 10,000 inhabitants. Although individually rare, together, rare diseases affect 
significant part of the population. Therefore, patient access to orphan medicines 
is receiving increasing political attention in the EU. The objective of our study 
was to determine the access to orphan medicines in Serbia. METHODS: Serbian 
Reimbursement List has been reviewed and identified orphan medicines were 
crossed with the List of orphan drugs in Europe, published in July 2011, available 
from Orphanet. The analysis of regulatory traits was based on a review of official 
documents setting out legislation regarding rare diseases and orphan medicines 
in Serbia. RESULTS: Only 6.5% (4 out of 61) of authorised orphan medicines in 
Europe with prior orphan designation and 25.0% (17 out of 68) without prior 
orphan designation were available and reimbursed in Serbia. According to the 
first level of the ATC Classification System, most of reimbursed orphan 
medicines belonged to the group L – ‘Antineoplastic and immunomodulating 
agents’. It is estimated that there are approximately 500,000 patients suffering 
from rare diseases in Serbia. Although the National register for rare diseases 
does not exist, the Law on Health Care provides for the forming of the official 
centres of reference for rare diseases that have the obligation of diagnosing, 
treatment and patient counseling, but also of creation of National register. 
Neither policy measures nor research incentives for rare diseases exist in Serbia. 
CONCLUSIONS: The low share of reimbursed orphan drugs in Serbia may be due 
to incomplete compliance with legislation of EU and existence of domestic 
procedure for authorisation. The EU policy on treatment of rare diseases 
facilitate the penetration of orphan drugs on the EU market, but apparently there 
is also considerable budget impact on the availability of orphan medicines.  
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OBJECTIVES: The United States (US) and the European Union (EU) implemented 
regulations for encouraging the development of drugs for rare diseases. Criteria 
for Orphan designation is generally based on the number of patients affected by 
the disease (<200,000 US patients and <5 in 10,000 EU patients). The EU also 
requires that a satisfactory alternative treatment is not available or that the new 
drug is significantly better than drugs currently marketed. We examined the 
characteristics of orphan drug (OD) designations and approvals by the US Food 
and Drug Administration (FDA) and the European Medicines Agency (EMA) 
between 2000 and 2011. METHODS: Data for orphan designations and approvals 
were extracted from the FDA and EMA online databases for the period 2000-2011. 
Data were updated to September 14, 2012. The time for OD designation to 
approval was estimated. Descriptive analysis, chi-square test, and group 
comparison t-tests were used in the analysis. RESULTS: The FDA granted 1558 
orphan designations for 1133 different products, and 149 approvals (9.6% of 
designated products), and the EMA 935 designations for 639 different products 
and 88 (9.4%) approvals during the study period. The time from OD designation 
to approval was 2.74±2.39 years in the FDA and 3.31±1.99 years in EME (p<0.05). 
EMA approved a larger number of designations (15.2%) than the FDA (12.3%) for 
the 569 products designated by both agencies; 67% of these products were first 
designated by the FDA and 78% of the 50 products approved by both agencies 
were approved first by EMA (p<0.001). CONCLUSIONS: The EU had more 
restrictive criteria for orphan designation and significantly longer approval 
times, less orphan designations, and fewer product approvals than the US. 
Harmonization of the Orphan drug regulatory processes of FDA and EME could 
result in improved access to ODs in the US and the EU.  
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OBJECTIVES: Opioid abuse is a significant public health problem in the United 
States, with opioid-related overdoses accounting for over 16,500 deaths per year. 
In addition, opioid abuse imposes a significant economic burden due to 
increased health care utilization and costs. This study calculates updated, payer-
specific, excess medical costs of diagnosed opioid abuse among commercially-
insured, Medicaid, and Medicare patients with recent prescription opioid (RxO) 
use. METHODS: Using de-identified Truven MarketScan medical and pharmacy 
claims data for commercially-insured, Medicaid, and Medicare patients, we 
examined the excess costs of diagnosed opioid abuse among patients with at 
least one pharmacy claim for an RxO, 2009-2011. Diagnosed abusers were 
identified using ICD-9 diagnosis codes for opioid abuse/dependence and were 
matched to non-abusers using propensity score methods. Medical costs were 
calculated over a 12-month period around the index date, which was the date of 
the first abuse diagnosis for abusers and the date of a random medical claim for 
non-abusers. Costs reflected payments by insurers as well as out-of-pocket 
patient costs, measured in 2011USD. The excess costs of diagnosed opioid abuse 
were calculated as the difference in costs between abusers and non-abusers 
following matching and included inpatient, emergency room (ER), and outpatient 
services. RESULTS: A total of 2510 commercially-insured, 536 Medicaid, and 268 
Medicare patients with diagnosed opioid abuse were matched to non-abusers. 
The annual per patient excess medical costs associated with diagnosed opioid 
abuse were $9,456 (p<0.001) for commercially-insured patients, $11,501 (p<0.001) 
for Medicaid patients, and $10,046 (p<0.001) for Medicare patients. Inpatient 
costs accounted for 63.0%-78.6% of total excess medical costs, and ER costs 
accounted for 5.6%-12.6% of total excess medical costs. CONCLUSIONS: The 
excess medical costs of opioid abuse are substantial and reveal a consistent 
pattern across payers. These estimates are comparable to prior research, 
suggesting opioid abuse continues to impose significant economic burden.  
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OBJECTIVES: Opioids, generally recommended as second- or third-line agents for 
neuropathic pain (NeP), are commonly used. This study characterized opioid and 
antiepileptic drug (AED) utilization among patients with NeP associated with 
diabetic peripheral neuropathy (DPN), HIV, spinal cord injury (SCI), chronic low-
back pain (CLBP), post-trauma/post-surgery (PTPS), and small-fiber involvement 
(SF) stratified by pain severity (mild, moderate, severe). METHODS: Data were 
from an observational study of NeP patients recruited during routine visits with 
primary-care or specialty physicians. Subjects completed a one-time 
questionnaire, and investigators completed a case report form based on a 6-
month retrospective chart review. Pain severity was based on the Brief Pain 
Inventory average pain score. RESULTS: A total of 624 subjects were enrolled: 
71.8% were white; 55.4% were male; mean age was 55.5±13.7 years; with a mean 
of 7.8±6.8 years since NeP diagnosis. The proportion of patients with each NeP 
indication was similar (16.0%-17.9%). Pain severity was mild, moderate, and 
severe in 17.6%, 47.6%, and 33.2%, respectively. The most frequently used NeP 
medications over the past 6 months were opioids (53.0%) and AEDs (49.0%), 
ranging from 33.0% (DPN) to 81.1% (CLBP) for opioids, and 28.3% (CLBP) to 64.1% 
(SCI) for AEDs. Overall, AED use remained unchanged across pain severity 
categories (46.4%-50.5%), while opioid use increased significantly with greater 
pain severity: 28.2% mild, 53.2% moderate, 65.2% severe (p<0.0001). Opioids were 
used by substantial proportions of patients across all pain severity levels 
including 33.3% in SCI, 50.0% in CLBP, and 71.4% in PTPS. Except for DPN, strong 
short-acting opioids were the most frequently used opioid class, ranging from 
14.3% in DPN to 55.7% in CLBP. CONCLUSIONS: Patterns of opioid use observed in 
this study were not fully consistent with published guidelines; opioid use was 
common across six different chronic NeP conditions and did not appear to be 
reserved for more severe pain patients.  
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OBJECTIVES: Evaluation of measures of medication-taking behavior is 
uncommon with infusible pharmacologic agents. This study evaluated 
persistence and adherence measures from utilization data on the infusible anti-
inflammatory biologic infliximab. METHODS: Patients were identified through 
the electronic health records (EHR) with ICD-9 diagnoses of rheumatoid arthritis 
(714.xx), psoriatic arthritis (696.xx), ulcerative colitis (556.xx), or Crohn’s disease 
(555.xx). Incident infliximab-treated patients between January 1, 2007 and June 
30, 2011, ≥18 years of age, with ≥1 maintanence dose were included. Infliximab 
dosing data were extracted from medical chart review and the EHR. We 
employed Kaplan-Meier (KM) analyses to estimate median time to treatment 
discontinuation and Cox regression to evaluate factors associated with 
discontinuation. Medication possession ratio (MPR) was calculated as sum of 
prescribed infusion frequency intervals divided by days from first infusion to last 
infusion. Compliance was defined as MPR ≥0.80. Proportion of days covered was 
also explored (data not shown). Sensitivity analyses were performed for various 
definitions of “treatment gap” and “discontinuation”. Analyses are shown for gap 
of ≥90 days. For all test statistics, a p-value <0.05 was considered statistically 
significant. RESULTS: We identified 122 patients meeting study inclusion criteria. 
Mean age of patients was 45 years and 61% were female. KM estimated a median 
treatment duration of 23 months and adjusted Cox regression identified African 
Americans at significantly greater risk for treatment discontinuation than 
Caucasians (hazard ratio: 4.95; 95% confidence interval: 1.11, 22.05; P=0.036). A 
total of 100 patients had a calculable MPR, mean and median MPR were 0.937 and 
0.956, respectively, with 93% of patients compliant with treatment. Sensitivity 
analyses showed varied results depending on definitions. CONCLUSIONS: 
Patients receiving infliximab were overall compliant with therapy during a 
median of 23 months of treatment. Underlying definitions used with MPR and 
KM are important, and should be clinically meaningful and transparent.  
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OBJECTIVES: Managed care companies implemented step therapy (ST) policies to 
reduce utilization of infused biologics in new patients. The purpose of this 
analysis was to compare market shares for biologic products for plans identified 
with ST policies versus all other claims (Other) in a large US administrative 
database. METHODS: Data from all plans with a ST policy throughout 2010 were 
compared to all other biologic claims during the same time period using data 
from the Wolters Kluwer Prometis® and Medical databases. Available data 
included payer, prescription (Rx), diagnosis (Dx) and procedure (Px) claims with 
unique anonymised patient identifiers. For 2010, biologic claims were evaluated 
based on: patients with Rx data having at least one biologic prescription and 
patients with Rx and Px data, for the subset with ≥ 1 Rx claim (any type) and ≥ 1 
medical claim (all cause). The number and percentage of patients receiving a 
biologic in 2010, was described. A secondary analysis of only subcutaneous (SC) 
products in the Rx database was conducted. RESULTS: Sixteen different plans 
had a ST policy in 2010. There were 280,271 patients (5,960 ST and 275,927 Other) 
with at least one biologic in the Rx claims, 274,495 with at least one claim in the 
Rx and Px combined data (7,936 ST and 266,559 Other), and 271,635 with claims 
for SC biologics in the Rx data (5,853 ST and 267,379 Other). There was less than a 
4.6% difference in patient market share within any individual products, when 
comparing market shares of products within ST policies vs Other policies. These 
results were consistent for all Rx, Rx and Px, and for the Rx only cohort, 
including when restricted to only SC products. CONCLUSIONS: Policies designed 
to reduce overall patient proportions using infusion biologics suggest only a very 
modest effect in this population-level comparison.  
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OBJECTIVES: To evaluate the pattern of opioid analgesic use among children in 
the US using two large databases which are representative of the US 
Commercially insured and Medicaid populations. METHODS: A retrospective 
claims database study was conducted using the MarketScan Commercial 
Database (2006-2010) and the MarketScan Multi-state Medicaid Database  
(2006-2008). We included children 2-17 years of age who had a prescription claim 
for oral opioids excluding cough syrups. Children who had at least one 5-day or 
more supply of opioid prescription claims were included. An opioid length of 
therapy continued until there was a 6-day (or greater) gap to the next opioid 
prescription. A Kaplan-Meier curve was used to display the time to opioid 
discontinuation. RESULTS: Of 1,544,397 children in the Commercial database 
who had 1 or more opioid prescriptions, 488,606 children met all inclusion  
and exclusion criteria. Approximately 49% were girls and the overall mean  
age was 11.4 years. Using the first opioid episode during the 5-year study period, 
the mean length of opioid therapy was 8.2 days (median = 6 days). 91.2% 
(n=445,569) of children discontinued opioids (IR or ER) within 2 weeks. 40.1% 
(n=195,889) were on opioid for 5 days while 51.1% (249,680) of children  
used opioids between 6 and 14 days. The Kaplan-Meier curve shows that  
only 0.07% of children were on opioids for 12 weeks or more. Data from the 
Medicaid database were consistent with the Commercial database results. 
CONCLUSIONS: Ninety percent of children in both Commercial and Medicaid 
populations were prescribed opioids for 5 days to 2 weeks. Only 0.07% and 0.2% 
of children 2-17 years of age in the US Commercial and Medicaid population 
databases had opioid prescription claims for 12 weeks or more. This study shows 
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OBJECTIVES: The FDA is trying to reduce over-the-counter (OTC) product misuse 
by providing appropriate warnings on the Drug Facts panel. This study assessed 
relationship between consumers’ risk cognition of liver damage associated with 
inappropriate use of OTC acetaminophen products and their intention to 
perform protective behavior. METHODS: A within-subject experimental study 
design was employed to recruit adults visiting selected pharmacy stores in 
Houston. Respondents were randomly exposed to labels containing organ-
specific warnings for OTC acetaminophen products. Risk cognition measures 
(perceived severity, perceived vulnerability, response efficacy, and self-efficacy) 
and intention to perform protective behavior (always read warnings, use with 
more caution, and consult a pharmacist/physician) were recorded using a 7-
point Likert scale where 1=strongly disagree and 7=strongly agree. Spearman 
correlation and multiple linear regression analyses were performed controlling 
for demographics, usage characteristic, and attitude towards the use of OTC 
products, at an a priori significance level of 0.05 using SAS 9.3. RESULTS: A total 
of 200 completed surveys were obtained. Items measuring intention to perform 
protective behavior showed strong internal consistency (Standardized 
Chronbach’s alpha=0.8). Mean intention towards protective behavior (4.9 ± 1.3) 
was positively correlated with risk cognition measures: perceived severity 
(r=0.46288, p<0.0001), perceived vulnerability (r=0.35052, p<.0001), and response 
efficacy (r=0.30650, p<0.0001). Regression analysis indicated that a unit increase 
in perceived severity significantly increased the intention to read the warnings 
carefully (β=0.28092, p<0.0001) and consult a pharmacist/physician (β=0.30071, 
p<0.0001). A unit increase in perceived vulnerability significantly increased the 
intention to be more cautious (β=0.30381, p<0.0001) when using OTC 
acetaminophen products. CONCLUSIONS: Consumers demonstrating higher risk 
cognition of liver damage exhibited greater intention to perform protective 
behavior when using OTC acetaminophen products. Educational interventions 
targeting appropriate use of OTC products as per the Drug Facts panel could 
improve risk cognition, and thus intensify consumer intention to perform 
protective behavior.  
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OBJECTIVES: To examine treatment patterns of ankylosing spondylitis (AS) 
patients who initiated anti-tumor necrosis factor (TNF) and non-TNF biologic 
agents, via a visualization tool. METHODS: Patients with at least one AS 
diagnosis were identified from the Veterans Health Administration (VHA) 
Medical SAS and Medicare claims datasets. Patients identified from the VHA 
were required to be at least 18 years old, and those from Medicare at least 65 
years. AS patients who initiated therapy with anti-TNF and non-TNF biologic 
agents were identified. Switches from an anti-TNF to a non-TNF or vice versa 
within two years after initial treatment were examined. Initial treatment 
continuation and discontinuation rates were also calculated. Switching patterns 
up to two switches were identified using a processing language and illustrated in 
a data visualization tool. RESULTS: In the Medicare sample, 1159 AS patients 
initiated anti-TNF, of which 5.69% switched to another anti-TNF, 55.91% 
discontinued therapy and 35.72% remained on their initial therapy. A total of 532 
AS Medicare patients initiated a non-TNF, of which 1.5% switched to an anti-
TNF, and only 3.95% remained on the initial therapy. In the VHA sample, 1021 AS 
patients initiated therapy with an anti-TNF, of which 13.52% switched to another 
anti-TNF type, 49.56% discontinued therapy and 36.73% remained on their initial 
therapy. A total of 84 AS patients from the VHA initiated non-TNF therapy, of 
which 4.76% switched to an anti-TNF and no patients remained on their initial 
therapy. CONCLUSIONS: Patients who initiated anti-TNF therapy were more 
likely to remain with this therapy. The VHA sample had a higher switching rate 
than the Medicare sample. Data visualization tools can help present these 
complicated treatment flows effectively to researchers with a variety of 
specialties and backgrounds.  
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OBJECTIVES: An orphan drug is a drug developed specifically to treat a rare 
medical condition. It is unclear how well rare-disease patients in the Middle East 
are able to obtain orphan drugs. In this study, we provide a critical review of the 
literature on the availability of orphan drugs in the Middle East. METHODS: 
Using Medline and other internet-based search engines, a critical review of both 
English and Arabic literature and other documents was performed to identify 
and evaluate 1) the prevalence of rare diseases in the Middle East; 2) problems 
with diagnosis of rare diseases in Arab countries; 3) availability of orphan drugs 
in the Middle East; and 4) development by pharmaceutical companies of orphan 
drugs for Arab diseases. RESULTS: Approximately 2.8 million patients are 
estimated to be suffering from a rare disease in the Middle East. Genetic 
disorders such as haemoglobinopathies, glucose-6-phosphate dehydrogenase 
deficiency, and autosomal recessive syndromes have a presence throughout the 
Middle East, with the latter’s occurring in approximately 1 out of 3,500 newborns. 
The prevalence of Behcet disease was estimated to be 2.23, 1.35, and 1.25 per 
100,000 in Bahrain, Kuwait, and Oman, respectively. To help with diagnosis, the 
Centre for Arab Genomic Studies has constructed a rare-disease database. 
Despite the high expense of orphan drugs, some health care companies, such as 
Taiba, currently market and distribute orphan drugs. The Dubai Biotechnology & 
Research Park provides an environment for life sciences companies to work in 
the Middle East. CONCLUSIONS: In order to promote the treatment of rare 
diseases, Middle Eastern governments need to facilitate education and training 
of health care personnel; develop and execute a method for obtaining and paying 
for orphan drugs; and provide tax, marketing, and other incentives to domestic 
and international firms to develop drugs specifically for the diseases of most 
importance to Middle Eastern patients.  
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